IP Library Granted Patent US 11,840,741
Granted Patent B2
US 11,840,741 · App. 17/454,082 · Granted Dec 12, 2023

Analysis of chromatin using a nicking enzyme

Inventors: Chaithanya Ponnaluri (Ipswich, MA); Hang-Gyeong Chin (Ipswich, MA); Pierre O. Esteve (Ipswich, MA); Sriharsa Pradhan (Ipswich, MA)
Assignee: New England Biolabs, Inc.
C12Q1/6886C12Q1/6806C12Q1/6827C12Q1/6841C12Q1/6869C12Q2521/301C12Q2521/331C12Q2525/117C12Q2527/156C12Q2531/119C12Q2535/122C12Q2543/10C12Q2563/131C12Q2565/133C12Q2600/154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,840,741
App. No.
17/454,082
Granted
Dec 12, 2023
Kind
B2
Abstract

Provided herein, among other things, are various compositions and methods for analyzing chromatin. In some embodiments, the composition may comprise a mixture of a nicking enzyme, four dNTPs, at least one labeled dNTP and, optionally, a polymerase. In some embodiments, this method may comprise: obtaining a sample comprising chromatin, reacting the sample with the composition to selectively label the open chromatin in the sample, and analyzing the labeled sample.

Claims (12)

1. A method for detecting abnormal cells in or from a tissue section or biopsy wherein the abnormal cells have altered chromatin compared to normal cells, comprising:

(a) reacting the cells with a composition comprising a mixture of a nicking enzyme, four dNTPs, and at least one labeled dNTP, and a polymerase to selectively label the chromatin;

(b) incorporating the labeled dNTP into the chromatin of the cells to form labelled nucleic acid; and

(c) analyzing the pattern of labelled nucleic acid in the cells.

2. The method according to claim 1 , wherein (c) further comprises determining whether the pattern of labelled nucleic acid corresponds to a cancer diagnosis of the cells or tissues.

3. The method according to claim 1 , wherein prior to (a), making the cells permeable.

4. The method according to claim 1 , wherein the tissue section or biopsy is fixed.

5. The method according to claim 3 , wherein the tissue section or biopsy is fixed.

6. The method according to claim 1 , wherein after (b) reverse cross linking and isolating DNA from the cells.

7. The method according to claim 1 , wherein following (b), labelling nuclei from the cells with a primary antibody.

8. The method according to claim 7 , wherein after labelling with a primary antibody, labelling with a secondary antibody.

9. The method according to claim 7 , further comprising: visualizing the labelled nuclei using a fluorescent microscope.

Assignments (2)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2021
From: PONNALURI, CHAITHANYA; CHIN, HANG-GYEONG; ESTEVE, PIERRE OLIVIER; PRADHAN, SRIHARSA
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 058072/0069 →